Benefits
NRF2 pathway activation — strong mechanism
Sulforaphane is one of the most potent dietary activators of the NRF2/KEAP1 pathway — the master transcriptional regulator of antioxidant and phase II detoxification responses. Activation upregulates GST, NQO1, HO-1, and GCL expression. This is the foundational mechanism for the broader clinical research program. Effect size in vivo varies by tissue, dose, and individual, but the mechanism is well-established and reproducible.
Type 2 diabetes biomarkers — modest evidence
Bahadoran 2012 (Diabetes Res Clin Pract 96:348-354) — n=81 T2D patients on 10 g/day broccoli sprout powder × 4 weeks: reduced HOMA-IR, insulin, oxidized LDL. Axelsson 2017 (Sci Transl Med 9:eaah4477) — concentrated broccoli sprout extract × 12 weeks in 97 obese T2D patients: reduced fasting glucose and HbA1c, particularly in dysregulated subjects. Effects modest but consistent with NRF2 mechanism.
Autism spectrum disorder — striking original, mixed replication
Singh 2014 (PNAS 111:15550-15555, PMID 25313065) — n=44 young men with moderate-severe ASD, 50-150 μmol/day sulforaphane × 18 weeks: substantial ABC and SRS improvements, reversible after washout. Singh 2021 replication (PMC8146218, n=45 children, 15 weeks): NO significant effect on primary outcome. Politte/Avmacol® trial (NCT02909959) further testing. Honest framing: striking original signal, less compelling replication; reasonable low-risk adjunct given safety.
H. pylori modulation
Yanaka 2009 (Cancer Prev Res 2:353-360) — n=48 H. pylori-infected adults in Japan, 70 g/day broccoli sprouts × 8 weeks: reduced colonization markers (urea breath test, stool antigen) and gastric mucosal markers. Effects regressed after discontinuation — suppression rather than eradication. Reasonable dietary adjunct for H. pylori carriers; NOT replacement for triple-therapy eradication.
Cancer chemoprevention — preclinical strong, clinical limited
Extensive preclinical chemoprevention evidence: NRF2 activation, HDAC inhibition, phase I/II carcinogen detox modulation. Talalay/Fahey at Johns Hopkins pioneered this from the 1990s. Egner 2014 (Qidong China) showed enhanced excretion of airborne carcinogens. Modest changes in prostate cancer biomarkers in small trials. No large-scale outcome trials demonstrate cancer prevention in humans.
Cardiovascular markers and endothelial function
Animal models show sulforaphane reduces aortic inflammation and oxidative damage via NRF2 upregulation (Wang 2014, PMC3953421). Smaller human trials: modest reductions in CRP, oxidized LDL, improved endothelial function. Mechanistically coherent but clinical evidence base small and short-duration. Plausible CV-supportive role, not validated CV intervention.
Product form matters — myrosinase is critical
Glucoraphanin alone is biologically inactive — conversion to sulforaphane requires myrosinase enzyme. Sivapalan 2018 (Mol Nutr Food Res 62:1700911): plasma sulforaphane differs ~3-7× between glucoraphanin-only and glucoraphanin + active myrosinase products. Choose pre-formed sulforaphane OR glucoraphanin + active myrosinase (Avmacol®, Truebroc® with myrosinase) for predictable effect.
Mechanism of action
Glucoraphanin to sulforaphane conversion
In intact broccoli plants, glucoraphanin and the enzyme myrosinase are stored in separate cellular compartments. When tissue is damaged (chewing, chopping, fresh sprout consumption), they combine and myrosinase hydrolyzes glucoraphanin to release sulforaphane. Cooking destroys myrosinase — boiled broccoli has minimal sulforaphane production unless gut bacteria provide microbial myrosinase. The 'eat them raw' or 'lightly steam' culinary advice for broccoli traces directly to this enzymatic chemistry.
NRF2/KEAP1 pathway activation
Sulforaphane modifies specific cysteine residues on KEAP1 (the cytoplasmic suppressor of NRF2), disrupting the KEAP1-NRF2 interaction. Released NRF2 translocates to the nucleus, binds the antioxidant response element (ARE) on phase II detoxification gene promoters, and drives expression of dozens of cytoprotective enzymes. This is the central mechanism for both the antioxidant claims and the cancer chemoprevention rationale. The pathway is conserved across animal models and human cell lines.
Phase II enzyme induction
Downstream NRF2 targets include glutathione S-transferases (GSTs), NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), glutamate-cysteine ligase (GCL, rate-limiting glutathione synthesis enzyme), and multiple drug-metabolizing transporters. Collectively these enzymes detoxify electrophiles, quench reactive oxygen species, and conjugate xenobiotics for excretion. This is the molecular basis for the 'detoxification support' positioning that has emerged in the consumer wellness space.
Histone deacetylase (HDAC) inhibition
Sulforaphane and its metabolites also inhibit class I and II histone deacetylases at micromolar concentrations. HDAC inhibition is one of the proposed mechanisms for the cancer chemoprevention effects observed in preclinical models (epigenetic regulation of tumor suppressor expression). Effect size in vivo at dietary doses is debated.
Why broccoli sprouts >> mature broccoli
Broccoli sprouts (3-day-old germinated seeds) contain 20-100× more glucoraphanin than mature broccoli on a fresh-weight basis. Talalay's group demonstrated this concentration difference in 1997 and developed standardized sprout production techniques as a basis for reproducible chemoprevention research. Mature broccoli is still a worthwhile dietary source but cannot match sprout-based supplementation for therapeutic dose ranges.
Clinical trials
Landmark double-blind placebo-controlled RCT at MGH Lurie Center for Autism. 44 young men aged 13-27 with moderate-to-severe ASD randomized to broccoli sprout extract (50-150 μmol/day sulforaphane based on body weight) or placebo for 18 weeks, followed by 4 weeks no-treatment. Aberrant Behavior Checklist (ABC) and Social Responsiveness Scale (SRS) significantly improved in sulforaphane group. Effects reversed after washout. Clinicaltrials.gov NCT01474993, FDA IND 113542. Used freeze-dried broccoli sprout extract from Cullman Chemoprotection Center at Johns Hopkins.
RCT in 45 children with ASD randomized to sulforaphane vs. placebo for 15 weeks. Treatment effects on the primary outcome (Ohio Autism Clinical Impressions Scale) were not significant between groups at 7 and 15 weeks. Some metabolomic changes detected. Important counterweight to the 2014 PNAS finding — the original effect may be specific to older adolescents/adults with severe ASD rather than generalizable across age and severity. Politte Avmacol® replication (NCT02909959) results pending.
RCT in 81 patients with type 2 diabetes randomized to 10 g/day broccoli sprout powder (BSP), 5 g/day BSP, or placebo for 4 weeks. High-dose group showed reduced insulin resistance (HOMA-IR), serum insulin, and oxidized LDL. Establishes a clinical signal in T2D consistent with NRF2-mediated reduction of oxidative stress and improvement in insulin sensitivity. Subsequent Axelsson 2017 (Sci Transl Med 9:eaah4477) extended this in 97 obese T2D patients on concentrated extract for 12 weeks, with reduced fasting glucose and HbA1c.
RCT in 48 H. pylori-infected adults in Japan randomized to 70 g/day broccoli sprouts (rich in glucoraphanin) or alfalfa sprouts placebo for 8 weeks. Sprout group showed reduced urea breath test values and stool H. pylori antigen. Effects regressed after sprout discontinuation. Suggests suppression rather than eradication; complementary to but not replacement for clinical eradication therapy.